Take­da bumps En­tyvio peak sales, lays out dengue vac­cine plans and celi­ac pipeline in lat­est earn­ings call

Take­da pro­ject­ed op­ti­mism in Thurs­day’s first-half fis­cal earn­ings call across its port­fo­lio, an­nounc­ing a boost in peak sales es­ti­mates for its al­ready block­buster IBD med …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER